Business
Santhera to share latest on commercial rollout of AGAMREE® and future strategic priorities at Capital Markets Day
Pratteln, Switzerland, March 24, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces that at its Capital Markets Day (CMD) in Zurich today, the Company will discuss the commercial progress with the global roll-out of AGAMREE® for the treatment of Duchenne Muscular Dystropy (DMD). The Company will also outline plans for further market expansion and provide an update on its strategic direction beyond DMD. The Company continues to evaluate opportunities to expand its rare disease portfolio as par
About this update from Santhera Pharmaceuticals Holding Ag
[{"type":"image","alt":"Santhera Pharmaceuticals Holding AG","displaySize":"","headline":null,"caption":"Santhera Pharmaceuticals Holding AG","className":"","disableSlideshowImg":false,"size":{"original":{"width":235,"height":71,"url":"https://media.zenfs.com/en/globenewswire.com/69b76b9d28605c9cb06e9f424ed2d9b3"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/m.yMU32TDRiiNbpVl.Y_mw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyNztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/69b76b9d28605c9cb06e9f424ed2d9b3","width":235,"height":71}},"lazy":false},{"type":"text","content":"Pratteln, Switzerland, March 24, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces that at its Capital Markets Day (CMD) in Zurich today, the Company will discuss the commercial progress with the global roll-out of AGAMREE® for the treatment of Duchenne Muscular Dystropy (DMD). The Company will also outline plans for further market expansion and provide an update on its strategic direction beyond DMD. The Company continues to evaluate opportunities to expand its rare disease portfolio as part of its strategy to establish itself as a leading specialty pharmaceutical company.","length":584,"tagName":"p"},{"type":"text","content":"The CMD will feature presentations from Santhera’s leadership team, including Dario Eklund, CEO; Dr Shabir Hasham, Chief Medical Officer; and Catherine Isted, Chief Financial Officer. Additionally, Prof. Luca Bello MD, PhD, Associate professor of neurology, and neuromuscular clinician at the University of Padova, will provide insights into the significant unmet medical need and current treatment landscape for patients with DMD.","length":432,"tagName":"p"},{"type":"text","content":"Dario Eklund, CEO of Santhera said: "The last 12 months have been a pivotal period for both the Company and DMD patients, as we began the global commercial roll-out of AGAMREE. Today, we are pleased to share an update on our strong progress with this breakthrough treatment and outline near and medium-term strategic goals for the Company. As we continue to execute our plans, our focus remains on improving patients’ quality of life whilst delivering value for our shareholders."","length":490,"tagName":"p"},{"type":"text","content":"Event details:Santhera’s Capital Market Day will be held today for institutional investors, analysts and business journalists from 2:00 ...